Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma

被引:33
|
作者
Su, Tung-Hung [1 ,2 ]
Liu, Chun-Jen [1 ,2 ]
Tseng, Tai-Chung [1 ,2 ]
Chou, Shih-Wan [1 ]
Liu, Chen-Hua [1 ,2 ]
Yang, Hung-Chih [1 ]
Wu, Shang-Ju [3 ]
Chen, Pei-Jer [1 ,2 ,4 ,5 ]
Chen, Ding-Shinn [1 ,2 ,4 ,6 ]
Chen, Chi-Ling [4 ]
Kao, Jia-Horng [1 ,2 ,4 ,5 ]
机构
[1] Natl Taiwan Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Div Hematol, Dept Internal Med, Taipei, Taiwan
[4] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan
[6] Acad Sinica, Genom Res Ctr, Taipei, Taiwan
关键词
VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; HIGH PREVALENCE; CANCER; MALIGNANCIES;
D O I
10.1111/apt.15132
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Chronic hepatitis B has been linked to lymphoma with contradictory results. Aim To investigate the association between chronic hepatitis B and lymphoma by using a nationwide population-based cohort. Methods Records of patients diagnosed with chronic hepatitis B (hepatitis B virus [HBV] cohort) or without (non-HBV cohort) during 2004-2007 were retrieved from the Taiwan National Health Insurance Research Database. Age, sex, comorbidities, and medical visits were matched using propensity scores between both cohorts, and they were followed up longitudinally until 2012 to determine any new lymphoma development. Results A total of 203 031 patients were included in each cohort with a mean follow-up of 7-9 years. The lymphoma incidence rate was significantly higher in the HBV cohort than in the non-HBV cohort (29.4 vs 15.9 per 100 000 person-years, P < 0.0001). After adjustment for comorbidities and medical visits, HBV infection was found to be an independent risk factor associated with the development of lymphoma (hazard ratio [HR]: 2.07, 95% confidence interval [CI]: 1.76-2.43, P < 0.0001) and non-Hodgkin's lymphoma (HR: 2.18, 95% CI: 1.80-2.65, P < 0.0001); specifically with an increased risk of diffuse large B-cell lymphoma (HR: 2.69, 95% CI: 2.05-3.52, P < 0.0001), other B-cell lymphoma (HR: 3.11, 95% CI: 1.89-5.11, P < 0.0001), and also for multiple myeloma (HR: 1.63, 95% CI: 1.10-2.42, P = 0.016). The association was significant even after excluding lymphoma development within the first year (HR: 2.08, 95% CI: 1.75-2.47, P < 0.0001). Conclusions Chronic hepatitis B is temporally associated with a 2-fold increased risk of lymphoma, particularly with B-cell non-Hodgkin's lymphoma, and also an increased risk for multiple myeloma.
引用
收藏
页码:589 / 598
页数:10
相关论文
共 50 条
  • [21] Hepatitis B Infection Is Associated with an Increased Risk of Non-Hodgkin Lymphoma: A Meta-Analysis.
    Dalia, Samir
    Chavez, Julio
    Castillo, Jorge J.
    Sokol, Lubomir
    BLOOD, 2012, 120 (21)
  • [22] High prevalence of hepatitis B virus infection in B-cell non-Hodgkin lymphoma
    Bianco, E.
    Marcucci, F.
    Mele, A.
    Spada, E.
    Candido, A.
    Pulsoni, A.
    Chionne, P.
    Madonna, E.
    Cotichini, R.
    Barbui, A.
    De Renzo, A.
    Iannitto, E.
    Liso, V.
    Martino, B.
    Montanaro, M.
    Pagano, L.
    Musto, P.
    Rapicetta, M.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S168 - S168
  • [23] B-cell non-Hodgkin's lymphoma of small lymphocytes
    Novosad, O.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S22 - S22
  • [24] Thymic B-cell non-Hodgkin's lymphoma in a child
    Azuma, E
    Nishihara, H
    Qi, J
    Nagai, M
    Hiratake, S
    Zhang, XL
    Komada, Y
    Hamazaki, M
    Sakurai, M
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 57 (01) : 48 - 50
  • [25] Emerging drugs in B-cell non-Hodgkin's lymphoma
    Kassam, Shireen
    Montoto, Silvia
    EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (02) : 323 - 343
  • [26] Use of bortezomib in B-cell non-Hodgkin's lymphoma
    Wang, Michael
    Zhou, Yuhong
    Zhang, Liong
    Nguyen, C. Ann
    Romaguera, Jorge
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (07) : 983 - 991
  • [27] RADIOIMMUNOTHERAPY IN THE PATIENT WITH B-CELL NON-HODGKIN'S LYMPHOMA
    Fernandez Natalia, Garcia
    Cuellar Angeles, Flores
    Santiago Maria del Rosario, Mora
    Perez Cristina, Gonzalez
    ATENCION FARMACEUTICA, 2012, 14 (01): : 34 - +
  • [28] HCV and HGV in B-cell non-Hodgkin's lymphoma
    Ellenrieder, V
    Weidenbach, H
    Frickhofen, N
    Michel, D
    Prümmer, O
    Klatt, S
    Bernas, O
    Mertens, T
    Adler, G
    Beckh, K
    JOURNAL OF HEPATOLOGY, 1998, 28 (01) : 34 - 39
  • [29] Antibody therapy of non-Hodgkin's B-cell lymphoma
    Paul Chinn
    Gary Braslawsky
    Christine White
    Nabil Hanna
    Cancer Immunology, Immunotherapy, 2003, 52 : 257 - 280
  • [30] Primary B-cell non-Hodgkin's lymphoma of the prostate
    Madhusudan, S
    John, LH
    Gillatt, D
    Price, CGA
    Pawade, J
    JOURNAL OF PATHOLOGY, 1999, 189 : 21A - 21A